Treatment for Subclinical Hyperthyroidism Causing Weight Loss

Diagnostic Confirmation

Confirm the diagnosis with repeat TSH, Free T4, and T3 measurements within 2-4 weeks of initial abnormal results 1
Ensure normal Free T4 and T3 levels to distinguish subclinical from overt hyperthyroidism 3

Treatment is strongly recommended for patients with TSH levels consistently below 0.1 mIU/L due to increased risks of cardiac complications, bone mineral density loss, and progression to overt hyperthyroidism 1, 2
The American Medical Association recommends treatment for patients with TSH < 0.1 mIU/L due to a 3-fold increased risk of atrial fibrillation in patients ≥60 years 2
Significant bone mineral density loss, especially in postmenopausal women, is a concern for patients with TSH < 0.1 mIU/L 1, 2
Increased cardiovascular mortality (up to 3-fold) in individuals >60 years is associated with TSH < 0.1 mIU/L 4
Postmenopausal women with TSH 0.1-0.4 mIU/L should consider treatment due to risk of bone mineral density loss 2

Beta-Blockers can be used for symptomatic relief while awaiting definitive treatment, and have been shown to decrease atrial premature beats and improve cardiac parameters 2

Monitor thyroid function tests (TSH, Free T4, T3) every 4-6 weeks during initial treatment 1
Target TSH level should be within normal reference range 1
Treatment of subclinical hyperthyroidism can stabilize bone mineral density, particularly in postmenopausal women 2